Ipsalazide
(Synonyms: 伊普柳氮) 目录号 : GC30608
Ipsalazide是一种新的柳氮磺吡啶类似物，旨在释放胃肠道中的5-氨基水杨酸和无毒载体分子。
Cas No.:82101-17-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ipsalazide is a novel sulfasalazine analog designed to release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract.
Sulfasalazine exerts beneficial effects in colitis by releasing 5-aminosalicylic acid in the colon, but its use can be limited by side effects. Ipsalazide is designed which the sulfapyridine of sulfasalazine has been replaced by carrier molecules[1].
No deaths or visible abnormalities occurrs within 7 days of a single oral dose of ipsalazide (4 g/kg in mice or 2 g/kg in rats). No abnormalities were seen at postmortem. The ipsalazide carrier molecule (ABG) is readily absorbed, with nearly half of the dose appearing in the urine. However, around 40% of the ABG was not recovered, and it is possible that this has undergone further metabolism, with loss of the aromatic amine function which is the basis for the colorimetric measurement of ABG[1].
[1]. Chan RP, et al. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983 Jul;28(7):609-15.
Animal experiment: | Rats[1] Maximum single doses administered orally are 2 g/kg body weight to 10 male and 10 female Biorex Wistar rats and 4 g/kg to 10 male and 10 female Swiss albino mice. The animals are observed for 7 days, any mortalities are recorded, and a full postmortem performed. |
References: [1]. Chan RP, et al. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983 Jul;28(7):609-15. | |
| Cas No. | 82101-17-5 | SDF | |
| 别名 | 伊普柳氮 | ||
| Canonical SMILES | O=C([O-])C1=CC(/N=N/C2=CC=C(C(NCC([O-])=O)=O)C=C2)=CC=C1O.[Na+].[Na+] | ||
| 分子式 | C16H11N3Na2O6 | 分子量 | 387.25 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5823 mL | 12.9116 mL | 25.8231 mL |
| 5 mM | 0.5165 mL | 2.5823 mL | 5.1646 mL |
| 10 mM | 0.2582 mL | 1.2912 mL | 2.5823 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet